High-dose chemotherapy in multiple myeloma. Leukemia 1997; 11(Suppl. 5): 27±31.Goldschmidt H, Hegenbart U, Wallmeier M, Moos M, Haas R. High-dose chemotherapy in multiple myeloma. Leukemia. 1997;11(Suppl 5):S27–31.Goldschmidt, H, Hegenbart, U, Wallmeier, M, Moos, M, Haas, R...
Limited progress in the treatment of multiple myeloma (MM) has been obtained since the introduction of melphalan more than 20 years ago.Response rates to conventional therapy are only in the order of 50% and median survival averages two to three years. Prognosis is related to tumor load at ...
High dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myelomaHumansCombined Modality TherapyTransplantation, AutologousWhole-Body IrradiationSpecimen HandlingAdultAgedAntineoplastic Combined Chemotherapy ProtocolsMiddle AgedMultiple Myeloma...
High-dose (HD) chemotherapy with melphalan and autologous blood stem cell transplantation (ABSCT) for treatment of symptomatic multiple myeloma (MM) on an outpatient basis has been well established in the USA and Canada, whereas in Germany and Western Europe an inpatient setting is the current st...
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. High-dose therapy with supporting autologous stem-cell transplantation remains a controversial treatment for cancer. In multiple myeloma, first-line regime... JA Child,GJ Morgan,FE Davies,... - 《N Engl J Med》 被...
High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients Sixty-three patients with high tumor mass multiple myeloma were treated with high-dose chemotherapy and total body irradiation supported by autologous bloo......
Multiple myeloma is the most common indication for high-dose chemotherapy with autologous stem cell support (ASCT) in North America today. Stem cell procurement for ASCT has most commonly been performed with stem cell mobilization using colony-stimulating factors with or without prior chemotherapy. The...
Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. BACKGROUNDHigh-dose chemotherapy with autologous hematopoietic progenitor cell (HPC) transplantation improves survival for patients with multiple myeloma (... BT Brinker...
High-dose chemotherapy with carboplatin, cyclophosphamide and etoposide and autologous transplantation for multiple myeloma relapsing after a previous tran... High-dose chemotherapy with carboplatin, cyclophosphamide and etoposide and auto- logous transplantation for multiple myeloma relapsing after a previous ...
in patients with multiple myeloma is longer in patients who receive high-dose melphalan (Alkeran, GlaxoSmithKline) and undergo autologous stem cell transplantation (ASCT) than in those treated with the novel agent lenalidomide (Revlimid, Celgene) plus conventional chemotherapy (melphalan plus prednisone)...